ProCE Banner Activity

My Thoughts on When to Consider ADCs for Today’s Patients With Advanced NSCLC

Clinical Thought
Are antibody drug conjugates a true targeted therapy for NSCLC? Read my thoughts on why I believe ADCs are a great therapeutic option for patients with advanced NSCLC.

Released: April 20, 2021

Expiration: April 19, 2022

Share

Faculty

Helena Yu

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Helena A. Yu, MD, has disclosed that she has received funds for research support paid to her institution from AstraZeneca, Cullinan Oncology, Daiichi Sankyo, Novartis, and Pfizer; and consulting fees from AstraZeneca, Blueprint, Daiichi Sankyo, and Janssen Oncology.